Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study.

Kang Wang,Hongfei Zhu,Hongming Yu,Yuqiang Cheng,Yanjun Xiang,Zhangjun Cheng,Yang Li,Tao Li,Dongxu Wang,Zhenyu Zhu,Shuqun Cheng

Journal of oncology（2023）

引用 1|浏览20

暂无评分

摘要

TACE combined with atezo/bev showed encouraging efficacy and an acceptable safety profile, making it a promising treatment option for patients with BCLC B HCC beyond the up-to-seven criteria, which will be further investigated in a prospective single-arm trial.

查看译文

关键词

hepatocellular carcinoma,bevacizumab,tace combined,atezolizumab,intermediate-stage,up-to-seven,single-arm

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要